Skip to Content

Find Comparable ETFs for SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF

XPH - PCX
ETF Category
Health & Biotech Equities
Asset Class
Equity
AUM
$206M
Expense Ratio
0.35% (Low)
Trading Volume
14.5K (Low)
Issuer
State Street
Number of Holdings
44
Inception Date
2006-06-19 (18 years)
Momentum
Very Weak Neutral Very Strong
AUM
Micro Small Very Large
Concentration
Very Low High Very High
Volatility
Very Low Low Very High
Overview
Momentum
Concentration
ESG
P/E Ratio
10.54
Annual Dividend Rate
1.45%
Beta
0.84
50-Day Moving Average
$44.23
Price vs. 50-Day MA
-0.20%
200-Day Moving Average
$43.66
Price vs. 200-Day MA
1.10%
1 Year Fund Flow
-$22M (-11% of AUM)
3 Year Fund Flow
-$5M (-2% of AUM)
5 Year Fund Flow
-$27M (-13% of AUM)
% in Top 10 Holdings (Market Cap Weighted)
40.19%
% in Top 15 Holdings (Market Cap Weighted)
57.75%
% in Top 50 Holdings (Market Cap Weighted)
100.01%
ESG Score
5.7500
ESG Peer %
28.38
ESG Global %
33.12
Carbon Intensity (Tons CO2e/$M Sales)
45
ESG Exclusion %
0.00
Sustainable Impact %
16.61

Invesco Pharmaceuticals ETF

PJP - PCX
View PJP's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Health & Biotech Equities
Equity
AUM: $285M
Expense Ratio: 0.56% (Moderate)
Volume: 8.7K (Very Low)
Issuer: Invesco
Holdings: 23
Inception: 2005-06-23 (19 years)
Neutral Momentum
Small AUM
Moderate Concentration
Low Volatility
Compare
Overview
Momentum
Concent.
ESG

correlation
A+

correlation

Measures how closely the two assets' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 84%

R-squared: 71%

This indicates a strong positive relationship between the price movements of these assets.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • PJP in XPH's comparables: No
  • XPH in PJP's comparables: Yes

A high score suggests the assets are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

valuation
A+

valuation

Compares valuation metrics to assess if the assets are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 17.24 vs 10.54

A high score indicates that the market values these assets similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • PJP Beta: 0.66 (Low)
  • XPH Beta: 0.84 (Low)
  • PJP 200-day Volatility: 11.88%
  • XPH 200-day Volatility: 14.76%

A high score suggests both assets have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • PJP Price vs 200-day MA: 102%
  • XPH Price vs 200-day MA: 101%

Performance Comparison:

Period PJP XPH
Year_1 10% 0%
Year_3 3% -4%
Year_5 9% 3%

A high score indicates both assets are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

geo
A+

geo

Evaluates the geographical similarity of the assets based on country, currency, and exchange.

  • Currency: USD vs USD
  • Exchange: PCX vs PCX

A high score indicates that both assets operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

sector
A+

sector

Compares the sector, industry, and other classifications of both assets.

  • ETF Category: Health & Biotech Equities vs Health & Biotech Equities

A high score indicates that the assets operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends.

Partial matches are considered for more nuanced comparisons, allowing for a higher score even when classifications are not identical but closely related.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • PJP Dividend Yield: 1%
  • XPH Dividend Yield: 1%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

P/E Ratio
17.24
Annual Dividend Rate
0.89%
Beta
0.66
50-Day Moving Average
$84.95
Price vs. 50-Day MA
1.86%
200-Day Moving Average
$85.05
Price vs. 200-Day MA
1.74%
1 Year Fund Flow
-$35M (-12% of AUM)
3 Year Fund Flow
-$168M (-59% of AUM)
5 Year Fund Flow
-$234M (-82% of AUM)
% in Top 10 Holdings
56%
% in Top 15 Holdings
77%
% in Top 50 Holdings
100%
ESG Score
5.7000
ESG Peer %
27.26
ESG Global %
32.37
Carbon Intensity
32
ESG Exclusion %
0.00
Sustainable Impact %
27.29
Toggle between similar ETFs and stocks for comparison.

Loading comparable ETFs ...

Invesco Pharmaceuticals ETF

PJP - PCX
A+
$86.53 +0.54 (0.63%)
Health & Biotech Equities
Equity
AUM: $285M
Expense Ratio: 0.56% (Moderate)
Volume: 8.7K (Very Low)
Issuer: Invesco
Holdings: 23
Inception: 2005-06-23 (19 years)
Neutral Momentum
Small AUM
Moderate Concentration
Low Volatility